ViiV Healthcare’s investigational broadly neutralising antibody – N6LS – successfully maintains viral suppression in long-acting treatment of HIV

FHS
March 13, 2025
10:18 am

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

Vaxart wins $453M in BARDA funding for oral Covid-19 vaccine

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 15, 2024

Electronic nudges improve flu vaccination rates in non-diabetic patients but fail to increase uptake in diabetics

Electronic nudges had a small impact on flu vaccine uptake in patients without diabetes but showed no significant effect among diabetic patients, suggesting the need

October 17, 2024

Five Weeknight Dishes: Ali Slagle’s school for zucchini skeptics – The Cannabist

By Ali Slagle, The New York Times So often when I happen upon zucchini in a dish, it seems uncomfortable to be there, its texture

August 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.